Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Peptic Ulcer Disease I: Introduction01:25

Peptic Ulcer Disease I: Introduction

Peptic ulcer disease (PUD) involves breaks in the gastrointestinal tract's mucosal lining, primarily in the stomach and duodenum, with less frequent occurrences in the lower esophagus or near the pylorus.Ulcers can be acute or chronic. Acute ulcers are short-lived with minimal inflammation and heal quickly after the irritant is removed. Chronic ulcers persist, may recur, and often cause scarring due to ongoing tissue damage. Superficial erosions affect only the mucosal layer and are called...
Peptic Ulcer Disease III: Clinical Manifestations and Complications01:25

Peptic Ulcer Disease III: Clinical Manifestations and Complications

Duodenal UlcersDuodenal ulcers are the most common form of peptic ulcer disease, presenting with chronic, intermittent epigastric pain. Pain typically appears 2–3 hours after meals, especially when the stomach is empty, often waking patients at night. It is characteristically relieved by food or antacids (“pain–food–relief”). Some patients remain asymptomatic until complications like bleeding or perforation emerge, particularly with NSAID or anticoagulant use.Gastric UlcersGastric ulcers share...
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Peptic Ulcer01:27

Peptic Ulcer

Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the mucus...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High consumption of risk medication and underutilization of proton pump inhibitors among patients with upper gastrointestinal bleeding due to peptic ulcers and erosions (BLUE study).

Scandinavian journal of gastroenterology·2025
Same author

Psychometric testing of the Norwegian version of the Simulation Design Scale, the Educational Practices Questionnaire and the Student Satisfaction and Self-Confidence in Learning Scale in nursing education.

International journal of nursing studies advances·2024
Same author

Nurse Anesthetist Practice Over 40 Years: A Repeated Cross-Sectional Study in Norway.

AANA journal·2023
Same author

Different pathways for preterm birth between singleton and twin pregnancies: a population-based registry study of 481 176 nulliparous women.

BJOG : an international journal of obstetrics and gynaecology·2022
Same author

Treatment and outcome of gastrointestinal bleeding due to peptic ulcers and erosions - (BLUE study).

Scandinavian journal of gastroenterology·2021
Same author

The Oslo Ischaemia Study: cohort profile.

BMJ open·2021

Related Experiment Video

Updated: Jun 12, 2026

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
03:05

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

[Risk factors for peptic ulcer bleeding].

Taran Søberg1, Bjørn Hofstad, Leiv Sandvik

  • 1Gastromedisinsk avdeling, Oslo universitetssykehus, Ullevål, 0407 Oslo, Norway. taran.soberg@bluezone.no

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|June 10, 2010
PubMed
Summary
This summary is machine-generated.

Most gastroduodenal ulcer bleeding patients use risky medications. Drug use increased significantly between 2002 and 2007, with higher rates of non-steroidal anti-inflammatory drugs (NSAIDs) and polypharmacy observed in bleeding patients compared to controls.

Related Experiment Videos

Last Updated: Jun 12, 2026

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
03:05

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Epidemiology

Background:

  • Many medications are associated with an increased risk of gastroduodenal ulcer bleeding.
  • Investigating the role of Helicobacter pylori infection and drug intake in gastroduodenal ulcer bleeding is crucial.

Purpose of the Study:

  • To examine Helicobacter pylori infection and drug use in patients with gastroduodenal ulcer bleeding.
  • To compare drug use patterns in 2002 versus 2007 among these patients.

Main Methods:

  • Prospective study of gastroduodenal ulcer bleeding patients in 2002 and 2007.
  • Data collection included Helicobacter pylori status and use of NSAIDs, aspirin, warfarin, clopidogrel, low-molecular heparin, SSRIs, corticosteroids, paracetamol, and PPIs.
  • Oslo residents aged over 60 in 2007 served as controls for drug use.

Main Results:

  • A significant increase in drug use was observed, from 78.2% in 2002 to 90.7% in 2007 (p=0.01).
  • Use of non-selective NSAIDs rose from 25.7% to 46.1% (p=0.001), and polypharmacy increased from 36.7% to 50.9% (p=0.02).
  • Patients with bleeding used more NSAIDs, aspirin, clopidogrel, low-molecular heparin, SSRIs, and corticosteroids compared to controls. H. pylori infection rates decreased but not significantly (51.0% in 2002 vs. 41.1% in 2007).

Conclusions:

  • The majority of gastroduodenal ulcer bleeding patients are on medications known to increase ulcer and bleeding risks.
  • Increased drug use, particularly NSAIDs and polypharmacy, is a significant trend in patients experiencing gastroduodenal ulcer bleeding.